Dear Colleagues
We are delighted to welcome you to the Aberdeen P&J live stadium in the summer of 2023. This will be the furthest north the BGCS has ever been, but believe me there is plenty of Scotland around and beyond to explore!
The focus of the meeting is going to be on “Research and Quality Improvement” in Gynaecological Oncology
The research topics would be on clinical trials and studies related to treatment; interventions especially contributing to existing evidence.
Areas on translational research contributing to improved clinical outcomes in the so called “omics world” of genomics, proteomics and metabolomics will be covered.
Quality improvement in patient care pathways will largely be influenced by a combination of cancer networks , multidisciplinary teams and in the near future due to technological advances such as data sciences, artificial intelligence , machine learning and deep learning within health organisations.
Let’s not forget the challenges of fertility preservation in Gynae-oncology patients.
Such exciting topics palatable even to surgeons will be discussed in BGCS 2023 and the venue is beautiful Aberdeen in Scotland!!!
Finally; plenty of fine whiskey and bonny company.
Welcome to Aberdeen.
Mary Cairns
Chair, Local Organising Committee
| Registration Type | Early rate | Late rate from 18th May 2022 | On site rate |
|---|---|---|---|
| Early Consultant (BGCS member) | £360 | £395 | £425 |
| Early Consultant (Non-member) | £420 | £455 | £500 |
| Early Fellows/Trainees (BGCS Member | £250 | £275 | £300 |
| Early Fellows/Trainees (Non-member) | £285 | £320 | £350 |
| Early Nurse/AHP (BGCS Member | £150 | £200 | £220 |
| Early Nurse/AHP (Non-member) | £175 | £235 | £260 |
| Early Student | £185 | £220 | £245 |
| Early Industry | £450 | £500 | £550 |
| Early Scientist/Non-Clinical | £240 | £265 | £285 |
Registration for the conference is now open. Book before Friday 6th May 2022 to take advantage of the early bird rates.
The registration fee for all delegates includes:
TERMS & CONDTIONS
Payment of Registration Fees
Full payment must be made by credit/debit card at the time of registering. Cards accepted are VISA, Visa Debit and MasterCard, unfortunately we cannot accept American Express or Maestro.
Full payment must be received in full prior to the conference. If you register at the early registration rate, payment must be received in full by the early registration deadline. If payment is not received at this time, your registration rate will automatically be changed to late registration and the higher fee will be due.
On receipt of your registration form, a confirmation email and receipt will be sent to you by the conference organisers. If you have not received this within 5 working days of registering, please contact the conference organisers by emailing bgcs@in-conference.org.uk.
Cancellation Terms
Notification of cancellation must be sent by email to bgcs@in-conference.org.uk, please ensure you receive an acknowledgment. If you cancel your place more than four weeks before the event date (on or before 10th June 2022) you will incur an administration fee of £40.00. If you cancel your place less than four weeks before the start of the conference (on or after 11th June 2022), the total conference fee will be charged and you will not receive any refund. Name changes however, will be permitted until 24 hours prior to the conference.
By submitting your registration, you agree to the terms of the cancellation policy.
TO REGISTER, PLEASE CLICK HERE.
Preconference Advanced Robotic Skills Course 5th – 6th July.
This 2 day robotic hands-on cadaveric course is an exclusive opportunity to enhance your knowledge and skills. Aimed at gynaecologists or senior registrars with early experience in robotic surgery, the course combines hands-on workshops, simulators, theoretical lectures and videos.
Cost: £1350
Please download course flyer for further details and how to register.
Pre-conference meetings, Wednesday 6th July 2022
In addition to the main conference programme, we will also be running two pre-conference meetings at the venue on Wednesday 6th July, which are free to attend for those registered for the annual scientific meeting.
We strongly advise you to register as soon as possible, via the registration link below, as there are limited spaces available.
Radiotherapy for Vulval Cancer
Held in conjunction with the Royal College of Radiologists (RCR), the meeting will include case based discussions on the management of primary, adjuvant and recurrent disease, as well as a contouring workshop and presentation of the new RCR vulval cancer contouring guidelines.
The day will be of interest to clinical oncology consultants and trainees, radiographers and physicists and will provide an excellent opportunity to meet with colleagues and discuss complex cases.
BSGOG Conference
The primary objectives of the BSGOG are to focus on surgical procedures, techniques, training/education, innovations and novel technologies, in addition to developing and promoting surgical trials.
The conference will include a series of informal presentations, surgical-videos and equipment/technology demonstrations, as well oral or video presentations covering any of the above BSGOG objectives. To submit an abstract for this session, please email britishsurgicalgog@gmail.com
Download Programme
Download Book of Abstracts
09.00 - 10.30
Session A – Diversity
10.30 - 11.00
Coffee break, Exhibition & Posters
11.00 - 12.30
Parallel Sessions
Session B – Early Diagnosis, Screening and Prevention
Session B2 – Diversity Workshop
12.30 - 13.30
Lunch, Exhibition & Posters
13.30 - 15.30
Parallel Sessions
Session C – Surgery
Session C2 – Non-Surgical Oncology
15.30 - 16.00
Coffee break, Exhibition & Posters
16.00 - 17.00
BGCS Short
17.05 - 18.00
BGCS AGM
19.00 - 23.30
Conference Dinner – Chelsea Old Town Hall
BGCS conference dinner.
The BGCS Conference Dinner will take place from 7–11pm on Thursday 7th July 2022 at the iconic Chelsea Old Town Hall.
Tickets are £50 and can be purchased during registration for the main conference. With your ticket you can expect drinks, food and entertainment (to be announced). This will provide a wonderful opportunity to network with colleagues, meet up with old friends and make new ones.
Places are limited so if you wish to register, please do so by following this link
Professor Leslie Walwyn
SESSION A – DIVERSITY
The Best Place for a Woman to Live
Dr Leslie Walwyn has been practicing general medicine and public health in Antigua and Barbuda for over twenty years. She has worked extensively in chronic disease prevention and health financing and was a PAHO consultant.
Currently, she leads the Global Health Track (GHT) at the American University of Antigua College of Medicine; an elective that spans undergraduate medical training. The GHT’s goal is to enhance awareness about vulnerable populations and produce skilled physicians who will impact communities and organizations globally and improve health outcomes.
She is passionate about mental wellbeing, childhood obesity, and diabetes and cervical cancer prevention and control.
Dr Esther Moss
The influence of racial and ethnic disparities on the incidence and management of endometrial cancer
Associate Professor Esther Moss is an academic gynaecological oncologist at the University of Leicester. She has a Masters in Clinical Oncology from the University of Birmingham and she was awarded a Wellbeing Research Training Fellowship to undertake a PhD at Keele University.
She was appointed as a subspecialist gynaecological oncologist at the University Hospitals of Leicester in 2012 and leads the Leicester Gynaecological Cancer Research Group.
Her research focuses on endometrial cancer genetics, biomarker discovery and health inequalities.
Professor Usha Menon
SESSION B – EARLY DIAGNOSIS, SCREENING & PREVENTION
Tackling the conundrum of ovarian cancer screening – future directions and new ways forward
Usha Menon, FRCOG, MD (Res) is Professor of Gynaecological Oncology at the MRC Clinical Trials Unit, at UCL, UK. She is known worldwide for her research on early detection of ovarian cancer.
Her work spans the largest ovarian cancer screening trials to date, in general (UKCTOCS) and high-risk (UKFOCSS) populations, risk prediction, early detection biomarkers, earlier diagnosis in symptomatic women and management of women at increased risk of the disease. This has contributed to the evidence base of current ovarian cancer screening guidelines in many countries. She oversees the trial biobanks with over half a million well-annotated samples and long-term follow-up through electronic health record linkage include 50,000 women with a unique set of longitudinal annual serum samples that precede cancer diagnosis. The latter supports numerous research collaborations investigating early detection biomarkers in multiple cancers.
Prof Jack Cuzick
Emerging cervical cancer screening strategies: self sampling and methylation biomarkers
Jack Cuzick is the John Snow Professor of Epidemiology at Queen Mary University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York.
His current interests are in prevention and screening. He has a long-standing interest in the role of HPV in cervical cancer screening and prevention and conducted the first study of HPV testing as part of cervical screening. He also leads the Predictors studies, comparing a range of HPV tests on the same sample. His current interests have focussed on the role of self-sampling for HPV as the primary screening test.
He was awarded CBE in 2017, and is a Fellow of the Royal Society, Academy of Medical Sciences and the Royal Statistical Society.
Professor Emma Crosbie
Screening, surveillance and prevention of endometrial cancer in Lynch syndrome
Professor Emma Crosbie is an NIHR Advanced Fellow, Professor and Honorary Consultant Gynaecological Oncologist at The University of Manchester. Her research focuses on screening, prevention and early detection of gynaecological cancers. Her clinical practice specialises in the fertility-sparing management and surgical care of women with endometrial cancer.
She is Chair of the NCRI Endometrial Workstream and Deputy Chair of the NCRI Screening, Prevention and Early Diagnosis Group. She is Chair of the RCOG Academic Board and member of the RCOG Blair Bell Research Society, roles that enable her to pursue her keen interest in nurturing the next generation of clinical academics.
Professor Mahendra Patel
SESSION B2 – DIVERSITY WORKSHOP
Inclusion and Diversity: COVID-19 supporting recruitment to clinical trials in primary care
Professor Mahendra G Patel OBE is a pharmacist and academic of national and international profile with professorial roles in the UK, Malaysia and USA. He has served the Royal Pharmaceutical Society for many years as national board member and as Treasurer. He has since been appointed member of the Teaching Faculty for Bioethics at UNESCO.
Mahendra has a number of national and international awards to his credit, especially around improving health and health inequalities in ethnic minority and underserved communities. In research, he is the Inclusion and Diversity Lead for the world’s largest clinical trials in primary care COVID-19 at the University of Oxford.
This year in the Queen’s New Year’s Honours, Mahendra was recognised for his outstanding work in pharmacy both nationally and internationally and was awarded an OBE.
Mrs Hilary Maxwell
With a nursing career spanning 16 years, including several roles as Matron, Hilary is currently a Gynae-Oncology Clinical Nurse Specialist at Dorset County Hospital Foundation Trust.
She previously worked for BBC North and was Director at a GP Practice responsible for change, transformation and people management. Her charitable experience includes establishing the Jill Dando Fund with radio and television presenter, Nick Ross and working as Executive Director at The National Endometriosis Society (now Endometriosis UK). Passionate about improving the lives of women with gynaecological cancers, she co-founded GO Girls in 2018, to ensure all women and their families receive grass roots support at every step of their difficult journey. She is also a regular speaker on the international conference circuit on women’s health and gynaecological cancers.
Professor Christina Fotopoulou
SESSION C – SURGERY
Radical Ovarian Cancer Cytoreduction in a PARP-I landscape
Christina Fotopoulou is a Professor of Gynaecological Cancer in the Department of Surgery and Cancer in Imperial College London, UK. She has served as the Chair of the guidelines committees of the European Society of Gynaecological Oncology and of the British Gynaecological Cancer Society. Her surgical and scientific expertise focusses on the management of patients with advanced and relapsed ovarian cancer, profiling of tumour heterogeneity and integration of tumour biology factors with surgical effort under the umbrella of individualisation of surgical care.
She is on the editorial board and reviewer of numerous international gynaecological and oncological journals and is member of various international oncological committees, including BGCS, ASCO, ESGO, IGCS, ESMO, ENGOT, AGO, SGO and NOGGO.
Mr Andy Nordin
Mr Andy Nordin is a surgical gynaecological oncologist and clinical director for cancer in East Kent. Andy is a clinical advisor to NCRAS (National Cancer Registration and Analysis Service) and is the Past-President of the BGCS (2016-19).
He has led the collaboration between the BGCS, Target Ovarian Cancer and Ovarian Cancer Action charities for the Ovarian Cancer Audit Feasibility Pilot, and chaired the project steering and management groups.
Andy was the gynaecology lead for the National Cancer Intelligence Network (NCIN) (2007-15), the Cancer Services Collaborative / NHS Improvement (2003-15) and the International Cancer Benchmarking Partnership (ICBP).
Professor Karol Sikora
Professor Karol Sikora is Chief Medical Officer of Rutherford Health. He was the founder of Cancer Partners UK which has created UK’s largest independent UK cancer network with private equity. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He was seconded to be Director of the WHO Cancer Programme in 2000. He was the Founding Dean and now Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and a Fellow of Corpus Christi College, Cambridge.
He has published over 300 papers and written or edited 20 books including Treatment of Cancer – the standard British postgraduate textbook, now going to its seventh edition in over 30 years. His book, The street-wise patients guide to surviving cancer, was published recently.
Nearly a year ago, he joined Twitter and now has over three hundred thousand followers. During the Covid crisis he has been dubbed the Positive Professor.
Professor Jonathan Ledermann
SESSION C2- NON-SURGICAL ONCOLOGY SUB-GROUP
Changing landscape in the treatment of endometrial and cervical cancer
Professor of Medical Oncology and Clinical Director at UCL Cancer Institute and a Consultant Medical Oncologist at UCL Hospitals, London. He has led national and international trials in ovarian cancer and until recently was Director of the CRUK & UCL Cancer Trials Centre, which he led for two decades.
He is a Senior Investigator for the NIHR, a Fellow of the Academy of Medical Sciences and Editor for ESMO Gynaecological Cancer Guidelines. He is the past Vice-President of ESGO and has published widely in the areas of clinical trials in gynaecological cancers, experimental therapeutics, guidelines and education in gynaecological malignancies.
Professor Naveena Singh
Pathology of endometrial and other gynaecological cancers with regard to checkpoint inhibitors
Naveena Singh is a consultant gynaecological pathologist/Clinical Professor at Vancouver General Hospital/University of British Columbia.
She has participated in the development of guidance documents in partnership with RCPath, NHSCSP, NICE, ESMO, the International Collaboration on Cancer Reporting (ICCR) and the World Health Organisation 5th Edition on Classification of Female Genital Tumours.
She has been President (2016-2019) of the British Association of Gynaecological Pathologists and
co-chairs the Education Committee of the International Society of Gynaecological Pathologists.
She has led several international collaborative research projects, co-authored over 130
peer-reviewed publications and is the co-editor of a series of textbooks on gynaecological pathology.
Dr Will Loughborough
Radiological assessment of response to systemic oncological therapy – challenges in the modern era of novel agents
After completing a post CCT diagnostic oncology imaging fellowship at the Royal Marsden hospital, Will took up a position as a Consultant Radiologist in Bath in 2019. As the departmental lead for oncology imaging, he has developed bespoke, personalised imaging protocols for cancer patients, orchestrated the radiology input into medical oncology trial recruitment and established a whole body MRI imaging service for breast and prostate cancer patients.
His sub-specialty interests centre around body oncology imaging, with regular involvement in the gastrointestinal, gynaecological and urology MDTs. As an accredited PET reporter, he has driven service development and research in PET imaging within the trust.
Will’s main academic interest is in radiological assessment of response to systemic therapies, particularly assessing how novel imaging techniques such as whole body MRI and PET tracers can help address challenging issues in this field. Additionally, he is the college tutor for radiology trainees in the trust where he has adapted the registrar training format to enhance participation in MDTs, increase exposure and competency in biopsy work and ringfence dedicated research time.
Dr Anna Olsson-Brown
How to set up a local support network for patients treated with check point inhibitors
Dr Anna Olsson-Brown is a consultant in medical oncology specialising in the management of skin cancers, sarcoma and pan-tumour immuno-toxicity. She established, and is the clinical lead, of a regional pan-tumour immunotherapy service.
She also has a research interest in the area of immunotherapy toxicity having completed her PhD in the area and is the oncology translational research committee lead for the immunotherapy toxicity work stream.
Professor Evis Sala
SESSION E – INNOVATION
Integrated Radiogenomic for Unravelling Tumour Heterogeneity and Treatment Monitoring in Ovarian Cancer
Dr Sala is the Professor of Oncological Imaging at University of Cambridge. Dr Sala’s research focuses on the development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging.
In recognition for her contribution to education and research in oncological imaging she received the Radiology Society of North America (RSNA) Honoured Educator Award in 2014, 2017 and 2020; was elected Fellow of the International Cancer Imaging Society, Fellow of the International Society for Magnetic Resonance in Medicine and Fellow of the European Society of Urogenital Radiology.
Dr Gareth Bryson
Innovation in Pathology Through Digitisation and Artificial Intelligence
Dr Gareth Bryson is a sub-specialist gynaecological pathologist in NHS Greater Glasgow and Clyde, was previously Head of Service for Pathology and is now Clinical Director. As part of an Innovate UK programme (iCAIRD) he is leading the digitisation of pathology in Glasgow which is the largest service in the UK.
In addition, Gareth is involved developing Artificial Intelligence algorithms with academic and industrial partners and bringing approved algorithms to the clinical service with the aim of improving efficiency and quality of reporting.
Suzanne Chapman
SESSION E2 – NURSING
Managing Pelvic Pain Secondary to Cancer Recurrence
Suzanne is a Senior Clinical Nurse Specialist in Pain Management at Imperial College Healthcare NHS Trust. She worked with the Pain Management service at the Royal Marsden Hospital from 2005 to 2022.
She has completed a BSc in Cancer Nursing and an MSc in Pain Management and has recently undertaken qualitative research exploring the needs of cancer survivors with persistent pain. Suzanne is well known in the field of cancer pain and has authored peer reviewed articles, national guidelines and has lectured nationally and internationally.
Professor Kevin Harrington
SESSION G – ONCOLOGY & NCRI
Evaluation of Immunotherapy and Radiotherapy Combinations in HPV-related Cancers
Kevin Harrington is an NIHR Senior Investigator and Head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research (ICR)/Royal Marsden Hospital (RMH).
He is the RMH/ICR NIHR Biomedical Research Centre lead for the Targeted Physical Therapies theme, Director for the ICR/RM CRUK RadNet Centre of Excellence, Chair of the CRUK Advanced Radiotherapy Network (ART-NET) Network Accelerator, Chair of the ICR Wellcome Trust Clinical Training Programme and an Executive Board member for the CRUK ICR/Imperial Major Centre for Convergence Science.
He is also an Honorary Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust and St George’s Hospital, specialising in developing new treatments for head and neck cancer.
Abstract Submission Now Open
Key Dates
Abstract Submission Deadline: 15 March 2022 17:00 (GMT)
Notification to Authors: Wednesday 20th April 2022
Submission
To submit an abstract, you need to log in into our Online Abstract Submission Site
Once you have created an account you can log in multiple times to complete your submission(s). Please remember to take a note of your password.
Abstract Format
The word limit for each abstract is 250 words. You need to provide a theme and a category for each abstract. All abstracts must be written and presented in English.
Submitted abstracts must be done via the Online Abstract Submission Site Abstracts not submitted via the site by the deadline will not be accepted.
Abstract Review
Review Panel
Each abstract will be reviewed by at least 2 reviewers from the Scientific Committee.
Notification to Authors
Authors will be notified about the outcome of their submissions during the week commencing 18th April 2022.
The notification will be sent to the submitting author only. Please do not call the office for details prior to this date, should you have any queries regarding the outcome of your submission. We are only able to give information to the person who submitted the abstract.
Click here for the full submission guidelines.
Details to follow.
The BGCS wishes to thank and acknowledge our 2022 conference sponsors:
PLATINUM
GOLD
SILVER
BRONZE
EXHIBITOR
If you would like to receive a copy of the sponsorship and exhibition brochure, please email bgcs@in-conference.org.uk
For UK Healthcare Professionals Only
GSK Sponsored Symposia
As one of our Platinum Sponsors, GSK will be offering delegates the opportunity to attend their Symposia, taking place in the Great Hall, on Friday 8th July.
There is no need to register in advance.
Early Morning Symposium * (breakfast will be provided)
09:00-09:30, Great Hall
Title
The GARNET trial – reshaping the advanced endometrial treatment landscape.
Welcome and introduction
Dr Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden, London (Chair).
The GARNET trial at ASCO: clinical outcomes from 2 years of survival follow-up
Dr Susana Banerjee
Application of GARNET trial data in clinical practice
Dr John McGrane, Consultant Clinical Oncologist, Royal Cornwall Hospitals, Truro.
Discussion
Moderated by Dr Susana Banerjee
Lunchtime Symposium **
13:10 -13:55, Great Hall
Title
A patient-centric, multidisciplinary approach to decision-making for first-line maintenance therapy in advanced ovarian cancer.
Welcome and introduction
Dr Rowan Miller, Consultant Medical Oncologist, University College London and St Bartholomew’s Hospitals, London, Chair.
Overview of first-line maintenance therapy options in newly diagnosed advanced ovarian cancer
Dr Rowan Miller
Patient case study – Clinical assessment
Ms Lisa Young, Macmillan Lead Gynae Cancer CNS, University Hospital Southampton NHS Foundation Trust, Southampton
PRIME and PRIMA clinical data presentation
Dr Clare Green, Consultant Medical Oncologist, University Hospital Southampton NHS Foundation Trust, Southampton
Patient case study – Patient-centric care
Ms Lisa Young
Multidisciplinary team discussion about patient management
Summary and close
Dr Rowan Miller
*This promotional symposium is funded and organised by GSK and will include information about the GSK-promoted product, ▼JEMPERLI (dostarlimab)
INDICATION: JEMPERLI (dostarlimab) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.1
JEMPERLI Prescribing Information – Great Britain is available here.
JEMPERLI Prescribing Information – Northern Ireland is available here.
1. JEMPERLI (dostarlimab) Summary of Product Characteristics.
**This promotional symposium is funded and organised by GSK and will include information about the GSK product, Zejula▼ (niraparib)
INDICATION: Zejula (niraparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Zejula is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.2
Zejula Prescribing Information – Great Britain is available here.
Zejula Precribing Information – Northern Ireland is available here.
2. Zejula (niraparib) Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK Limited on +44 (0) 800 221 441.
PM-GB-DST-WCNT-220005 | July 2022
CONFERENCE VENUE
P&J Live
East burn Road
Stoneywood
Aberdeen
AB21 9FX
The conference will be held at P&J Live, the North East of Scotland’s state-of-the art conference and events venue, offering world-class facilities, all sustainably powered by local, renewable energy sources.
With unrivalled public transport connections, the venue is located in close proximity to Aberdeen International Airport – the UK’s most connected regional airport, a few short minutes from the city’s western peripheral route, and in prime position for rail links between Aberdeen and the North of Scotland.
ABERDEEN
A city of strength and endurance; a city that reflects the ancient rock that in many ways makes it so memorable. But alongside the timeless beauty, Scotland’s third largest city also provides a warm embrace. Hospitality comes naturally to Aberdeen – and the Aberdonian. Delegates will experience a region often recognised as among the friendliest in the UK.
This is a world-class destination with a world-class reputation for providing a memorable welcome to every type and size of event, business meeting or conference.
Aberdeenshire holds an abundance of hidden delights. Delegates will feel at ease strolling through an attractive, people-friendly environment. The spectacular light of the North-east compliments the world-famous architecture. This is a city of fun, great nights out and serious cultural experience.
GETTING THERE
By Air
P&J Live is just 1.5 miles from Aberdeen International Airport, the UK’s most regionally connected airport, operating 45 UK flights daily from Newcastle, Manchester, Birmingham, Bristol, London and Dublin.
For further information, please visit the Aberdeen International Airport website:
www.aberdeenairport.com
By Rail
Located in the city centre, a short 15 minute journey from P&J Live, the railway station connects Aberdeen to the rest of the UK with a wide range of direct connections. Aberdeen is the latest destination in Scotland to benefit from the arrival of the world-class Azuma trains which are transforming travel for customers and communities along the East Coast route.
Board the Caledonian Sleeper from London Euston – which runs 6 nights a week – in the evening and wake up in Aberdeen
Dyce Train Station
P&J Live is just 1.5 miles from Dyce Train Station which offers regular connections north and south for event visitors travelling by rail. Dyce is on the Aberdeen-Elgin-Inverness line and is also served by some through trains from Glasgow and Edinburgh.
Trains run at least once an hour Monday to Saturday, less frequently on Sundays.
Aberdeen Train Station
Aberdeen Train Station is in the city centre, a ten-minute train journey from Dyce by rail, and is located next door to Union Square.
The following operators run trains to and from Aberdeen station:
BGCS 2023 Accommodation Options
The event complex comprises two on site hotels.
Hilton Aberdeen
The adjoining 4-star Hilton hotel has 200 bedrooms, an executive lounge, restaurant, spa and a suite of small meetings and event spaces.
Aloft Aberdeen
The 150 bedroom, 3-star Aloft hotel is the first of its kind in Scotland, featuring contemporary urban-style interiors, cutting edge technologies and live-music programming.
Meeting Secretariat
In Conference Ltd
Unit 1, Q Court
Quality Street
Edinburgh
EH4 5BP
Tel: +44 (0)131 336 4203
Email: BGCS@in-conference.org.uk
Please click below to view our Privacy Policy.